Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (nle(4),d-phe(7))alpha-msh
2. (nle(4)-dphe(7))alpha-melanocyte-stimulating Hormone
3. 4-nle-7-phe-alpha-msh
4. 4-norleucine-7-d-phenylalanine-alpha-melanocyte-stimulating Hormone
5. 4-norleucyl-7-phenylalanine-alpha-msh
6. Alpha-msh, Nle(4)-phe(7)-
7. Alpha-msh, Norleucyl(4)-d-phenylalanyl(7)-
8. Melanotan-1
9. Msh, 4-nle-7-phe-alpha-
10. Msh, 4-norleucyl-7-phenylalanine-alpha-
11. Mt-1 (nlefmsh)
12. Ndp-alpha-msh
13. Ndp-msh
14. Ndpmsh
1. Melanotan-1
2. 4-nle-7-phe-alpha-msh
3. Cuv1647
4. 75921-69-6
5. Cuv 1647
6. Cuv-1647
7. Qw68w3j66u
8. Scenesse
9. Mt-1 (nlefmsh)
10. Ac-ser-tyr-ser-nle-glu-his-d-phe-arg-trp-gly-lys-pro-val-nh2
11. Msh, 4-nle-7-phe-alpha-
12. Ndp-alpha-msh
13. Mt-i
14. Afamelanotide [inn]
15. Alpha-msh, Nle(4)-phe(7)-
16. 4-norleucyl-7-phenylalanine-alpha-msh
17. Afamelanotida
18. Afamelanotidum
19. Unii-qw68w3j66u
20. Msh, 4-norleucyl-7-phenylalanine-alpha-
21. Mbj 05
22. Alpha-msh, Norleucyl(4)-d-phenylalanyl(7)-
23. Afamelanotidemt-i
24. (nle(4)-dphe(7))alpha-melanocyte-stimulating Hormone
25. 4-norleucine-7-d-phenylalanine-alpha-melanocyte-stimulating Hormone
26. Afamelanotide [mi]
27. Afamelanotide [usan:inn]
28. Afamelanotide [usan]
29. (nle4-d-phe7)-alpha-melanocyte-stimulating Hormone
30. Afamelanotide [who-dd]
31. Alpha-melanotropin, 4-l-norleucine-7-d-phenylalanine-
32. Schembl22463810
33. Chebi:136034
34. Afamelanotide [orange Book]
35. [nle(4),d-phe(7)]-alpha-msh
36. 921a696
37. Nle(4)-d-phe(7)-alpha-melanocyte-stimulating Hormone
38. .alpha.-melanotropin (swine), 4-l-norleucine-7-d-phenylalanine-
39. Acetyl(4-(2s)-2-aminohexanoic Acid,7-d-phenylalanine)human Melanotropin Alpha
40. N-acetyl-l-seryl-l-tyrosyl-l-seryl-l-norleucyl-l-alpha-glutamyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophylglycyl-l-lysyl-l-prolyl-l-valinamide
41. N-acteyl-l-ser-l-tyr-l-ser-l-nle-l-glu-l-his-d-phe-l-arg-l-trp-gly-l-lys-l-pro-l-val-nh2
| Molecular Weight | 1646.8 g/mol |
|---|---|
| Molecular Formula | C78H111N21O19 |
| XLogP3 | -3.5 |
| Hydrogen Bond Donor Count | 23 |
| Hydrogen Bond Acceptor Count | 22 |
| Rotatable Bond Count | 51 |
| Exact Mass | 1645.83651040 g/mol |
| Monoisotopic Mass | 1645.83651040 g/mol |
| Topological Polar Surface Area | 643 Ų |
| Heavy Atom Count | 118 |
| Formal Charge | 0 |
| Complexity | 3360 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 12 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Affinity Labels
Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)
Anticarcinogenic Agents
Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. (See all compounds classified as Anticarcinogenic Agents.)
ABOUT THIS PAGE
97
PharmaCompass offers a list of Qw68W3J66U API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Qw68W3J66U manufacturer or Qw68W3J66U supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Qw68W3J66U manufacturer or Qw68W3J66U supplier.
PharmaCompass also assists you with knowing the Qw68W3J66U API Price utilized in the formulation of products. Qw68W3J66U API Price is not always fixed or binding as the Qw68W3J66U Price is obtained through a variety of data sources. The Qw68W3J66U Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Qw68W3J66U manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Qw68W3J66U, including repackagers and relabelers. The FDA regulates Qw68W3J66U manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Qw68W3J66U API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Qw68W3J66U supplier is an individual or a company that provides Qw68W3J66U active pharmaceutical ingredient (API) or Qw68W3J66U finished formulations upon request. The Qw68W3J66U suppliers may include Qw68W3J66U API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Qw68W3J66U as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Qw68W3J66U API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Qw68W3J66U as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Qw68W3J66U and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Qw68W3J66U NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Qw68W3J66U suppliers with NDC on PharmaCompass.
Qw68W3J66U Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Qw68W3J66U GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Qw68W3J66U GMP manufacturer or Qw68W3J66U GMP API supplier for your needs.
A Qw68W3J66U CoA (Certificate of Analysis) is a formal document that attests to Qw68W3J66U's compliance with Qw68W3J66U specifications and serves as a tool for batch-level quality control.
Qw68W3J66U CoA mostly includes findings from lab analyses of a specific batch. For each Qw68W3J66U CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Qw68W3J66U may be tested according to a variety of international standards, such as European Pharmacopoeia (Qw68W3J66U EP), Qw68W3J66U JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Qw68W3J66U USP).
